메뉴 건너뛰기




Volumn 6, Issue , 2016, Pages

Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

(15)  Serban, Maria Corina a,b   Sahebkar, Amirhossein c,d   Mikhailidis, Dimitri P e   Toth, Peter P f,g   Jones, Steven R g   Muntner, Paul a   Blaha, Michael J g   Andrica, Florina b   Martin, Seth S g   Borza, Claudia b   Lip, Gregory Y H h   Ray, Kausik K i   Rysz, Jacek j   Hazen, Stanley L k   Banach, Maciej j  


Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; LIPID; LIPOPROTEIN A;

EID: 84954432997     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19188     Document Type: Article
Times cited : (56)

References (69)
  • 1
    • 0242331117 scopus 로고    scopus 로고
    • Report of the national heart, lung, and blood institute workshop on lipoprotein (a) and cardiovascular disease: Recent advances and future directions
    • Marcovina, S. M., Koschinsky, M. L., Albers, J. J. & Skarlatos, S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clinical chemistry 49, 1785-1796 (2003).
    • (2003) Clinical Chemistry , vol.49 , pp. 1785-1796
    • Marcovina, S.M.1    Koschinsky, M.L.2    Albers, J.J.3    Skarlatos, S.4
  • 3
    • 73549097512 scopus 로고    scopus 로고
    • Genetic variants associated with Lp (a) lipoprotein level and coronary disease
    • Clarke, R. et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. New England Journal of Medicine 361, 2518-2528 (2009).
    • (2009) New England Journal of Medicine , vol.361 , pp. 2518-2528
    • Clarke, R.1
  • 5
    • 0032966485 scopus 로고    scopus 로고
    • Biochemical risk factors and patient's outcome: The case of lipoprotein (a)
    • Lippi, G. & Guidi, G. Biochemical risk factors and patient's outcome: the case of lipoprotein (a). Clinica chimica acta 280, 59-71 (1999).
    • (1999) Clinica Chimica Acta , vol.280 , pp. 59-71
    • Lippi, G.1    Guidi, G.2
  • 6
    • 0032498947 scopus 로고    scopus 로고
    • Modification of serum apolipoprotein AI, apolipoprotein B and lipoprotein (a) levels after bisphosphonates-induced acute phase response
    • Lippi, G., Braga, V., Adami, S. & Guidi, G. Modification of serum apolipoprotein AI, apolipoprotein B and lipoprotein (a) levels after bisphosphonates-induced acute phase response. Clinica chimica acta 271, 79-87 (1998).
    • (1998) Clinica Chimica Acta , vol.271 , pp. 79-87
    • Lippi, G.1    Braga, V.2    Adami, S.3    Guidi, G.4
  • 7
    • 84924968122 scopus 로고    scopus 로고
    • Lipoprotein (a): Influence on cardiovascular manifestation
    • Mellwig, K. et al. [Lipoprotein (a): influence on cardiovascular manifestation.]. Clinical research in cardiology supplements 10, 33-8 (2015).
    • (2015) Clinical Research in Cardiology Supplements , vol.10 , pp. 33-38
    • Mellwig, K.1
  • 8
    • 41549133097 scopus 로고    scopus 로고
    • Lipoprotein (a) levels and risk of future coronary heart disease: Large-scale prospective data
    • Bennet, A. et al. Lipoprotein (a) levels and risk of future coronary heart disease: large-scale prospective data. Archives of internal medicine 168, 598-608 (2008).
    • (2008) Archives of Internal Medicine , vol.168 , pp. 598-608
    • Bennet, A.1
  • 9
    • 84870059868 scopus 로고    scopus 로고
    • Lipoprotein (a) and risk of coronary, cerebrovascular, and peripheral artery disease the EPIC-norfolk prospective population study
    • Gurdasani, D. et al. Lipoprotein (a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease The EPIC-Norfolk Prospective Population Study. Arteriosclerosis, thrombosis, and vascular biology 32, 3058-3065 (2012).
    • (2012) Arteriosclerosis, Thrombosis, and Vascular Biology , vol.32 , pp. 3058-3065
    • Gurdasani, D.1
  • 10
    • 67651210632 scopus 로고    scopus 로고
    • Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
    • Collaboration, E. R. F. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA: the journal of the American Medical Association 302, 412 (2009).
    • (2009) JAMA: The Journal of the American Medical Association , vol.302 , pp. 412
    • Collaboration, E.R.F.1
  • 11
    • 84942416178 scopus 로고    scopus 로고
    • Lipoprotein (a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia
    • Vongpromek, R. et al. Lipoprotein (a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. Journal of internal medicine 278, 166-73 (2015).
    • (2015) Journal of Internal Medicine , vol.278 , pp. 166-173
    • Vongpromek, R.1
  • 12
    • 79954991685 scopus 로고    scopus 로고
    • Screening and therapeutic management of lipoprotein (a) excess: Review of the epidemiological evidence, guidelines and recommendations
    • Lippi, G., Franchini, M. & Targher, G. Screening and therapeutic management of lipoprotein (a) excess: review of the epidemiological evidence, guidelines and recommendations. Clinica Chimica Acta 412, 797-801 (2011).
    • (2011) Clinica Chimica Acta , vol.412 , pp. 797-801
    • Lippi, G.1    Franchini, M.2    Targher, G.3
  • 13
    • 77956849517 scopus 로고    scopus 로고
    • Lipoprotein (a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
    • Nicholls, S. J. et al. Lipoprotein (a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Journal of lipid research 51, 3055-3061 (2010).
    • (2010) Journal of Lipid Research , vol.51 , pp. 3055-3061
    • Nicholls, S.J.1
  • 14
    • 0031729223 scopus 로고    scopus 로고
    • Expression of adhesion molecules by Lp (a): A potential novel mechanism for its atherogenicity
    • Allen, S. et al. Expression of adhesion molecules by Lp (a): a potential novel mechanism for its atherogenicity. The FASEB journal 12, 1765-1776 (1998).
    • (1998) The FASEB Journal , vol.12 , pp. 1765-1776
    • Allen, S.1
  • 15
    • 0036063992 scopus 로고    scopus 로고
    • Lp (a) particles mold fibrin-binding properties of apo (a) in size-dependent manner a study with different-length recombinant apo (a), native lp (a), and monoclonal antibody
    • Kang, C. et al. Lp (a) Particles Mold Fibrin-Binding Properties of Apo (a) in Size-Dependent Manner A Study With Different-Length Recombinant Apo (a), Native Lp (a), and Monoclonal Antibody. Arteriosclerosis, thrombosis, and vascular biology 22, 1232-1238 (2002).
    • (2002) Arteriosclerosis, Thrombosis, and Vascular Biology , vol.22 , pp. 1232-1238
    • Kang, C.1
  • 16
    • 35148848559 scopus 로고    scopus 로고
    • New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease
    • Tsimikas, S., Tsironis, L. D. & Tselepis, A. D. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology 27, 2094-2099 (2007).
    • (2007) Arteriosclerosis, Thrombosis, and Vascular Biology , vol.27 , pp. 2094-2099
    • Tsimikas, S.1    Tsironis, L.D.2    Tselepis, A.D.3
  • 17
    • 0032895113 scopus 로고    scopus 로고
    • Atherogenecity of lipoprotein (a) and oxidized low density lipoprotein: Insight from in vivo studies of arterial wall influx, degradation and efflux
    • Nielsen, L. B. Atherogenecity of lipoprotein (a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis 143, 229-243 (1999).
    • (1999) Atherosclerosis , vol.143 , pp. 229-243
    • Nielsen, L.B.1
  • 18
    • 78649888517 scopus 로고    scopus 로고
    • Lipoprotein (a) as a cardiovascular risk factor: Current status
    • Nordestgaard, B. G. et al. Lipoprotein (a) as a cardiovascular risk factor: current status. European heart journal 31, 2844-2853 (2010).
    • (2010) European Heart Journal , vol.31 , pp. 2844-2853
    • Nordestgaard, B.G.1
  • 19
    • 79251601596 scopus 로고    scopus 로고
    • Guidelines for the primary prevention of stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association
    • Goldstein, L. B. et al. Guidelines for the primary prevention of stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation 42, 517-584 (2011).
    • (2011) Stroke; A Journal of Cerebral Circulation , vol.42 , pp. 517-584
    • Goldstein, L.B.1
  • 20
    • 84924934375 scopus 로고    scopus 로고
    • Lipids, blood pressure and kidney update 2014
    • Banach, M. et al. Lipids, blood pressure and kidney update 2014. Pharmacological Research 95, 111-125 (2015).
    • (2015) Pharmacological Research , vol.95 , pp. 111-125
    • Banach, M.1
  • 22
    • 84954423531 scopus 로고    scopus 로고
    • Tibolone can decrease lipoprotein(a) concentrations in postmenopausal women: A systematic review and metaanalysis of controlled trials
    • Kotani, K. et al. Tibolone can decrease lipoprotein(a) concentrations in postmenopausal women: a systematic review and metaanalysis of controlled trials. Eur Heart J 26(Suppl. 1), 286 (2015).
    • (2015) Eur Heart J , vol.26 , pp. 286
    • Kotani, K.1
  • 23
    • 84936995465 scopus 로고    scopus 로고
    • Tibolone decreases Lipoprotein (a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients
    • Kotani, K. et al. Tibolone decreases Lipoprotein (a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis 242, 87-96 (2015).
    • (2015) Atherosclerosis , vol.242 , pp. 87-96
    • Kotani, K.1
  • 24
    • 84871975694 scopus 로고    scopus 로고
    • PCSK9 inhibition-A novel mechanism to treat lipid disorders?
    • Banach, M. et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders? Current pharmaceutical design 19, 3869-3877 (2013).
    • (2013) Current Pharmaceutical Design , vol.19 , pp. 3869-3877
    • Banach, M.1
  • 25
    • 84922593883 scopus 로고    scopus 로고
    • Proprotein convertase subtilisin/kexin 9 inhibitors: An emerging lipid-lowering therapy?
    • Dragan, S., Serban, M. C. & Banach, M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy ? J Cardiovasc Pharmacol Ther, 20, 157-168 (2015).
    • (2015) J Cardiovasc Pharmacol Ther , vol.20 , pp. 157-168
    • Dragan, S.1    Serban, M.C.2    Banach, M.3
  • 26
    • 77949485460 scopus 로고    scopus 로고
    • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial
    • Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet 375, 998-1006 (2010).
    • (2010) The Lancet , vol.375 , pp. 998-1006
    • Raal, F.J.1
  • 27
    • 77949349469 scopus 로고    scopus 로고
    • Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
    • Ladenson, P. W. et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. New England Journal of Medicine 362, 906-916 (2010).
    • (2010) New England Journal of Medicine , vol.362 , pp. 906-916
    • Ladenson, P.W.1
  • 28
    • 48349088178 scopus 로고    scopus 로고
    • Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
    • Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J. & Rader, D. J. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature Clinical Practice Cardiovascular Medicine 5, 497-505 (2008).
    • (2008) Nature Clinical Practice Cardiovascular Medicine , vol.5 , pp. 497-505
    • Samaha, F.F.1    McKenney, J.2    Bloedon, L.T.3    Sasiela, W.J.4    Rader, D.J.5
  • 29
    • 79953699040 scopus 로고    scopus 로고
    • Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice
    • Merki, E. et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. Journal of the American College of Cardiology 57, 1611-1621 (2011).
    • (2011) Journal of the American College of Cardiology , vol.57 , pp. 1611-1621
    • Merki, E.1
  • 30
    • 84944152398 scopus 로고    scopus 로고
    • Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study
    • Tsimikas S. et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386, 1472-83 (2015).
    • (2015) Lancet , vol.386 , pp. 1472-1483
    • Tsimikas, S.1
  • 31
    • 84903717113 scopus 로고    scopus 로고
    • Lipid, blood pressure and kidney update 2013
    • Banach, M. et al. Lipid, blood pressure and kidney update 2013. International urology and nephrology 46, 947-961 (2014).
    • (2014) International Urology and Nephrology , vol.46 , pp. 947-961
    • Banach, M.1
  • 32
    • 84954438771 scopus 로고    scopus 로고
    • Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials
    • Sahebkar, A., Serban, C., Ursoniu, S. & Banach, M. Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition. 32, 33-40 (2016).
    • (2016) Nutrition. , vol.32 , pp. 33-40
    • Sahebkar, A.1    Serban, C.2    Ursoniu, S.3    Banach, M.4
  • 33
    • 39849088181 scopus 로고    scopus 로고
    • ATP production and TCA activity are stimulated by propionyl-L-carnitine in the diabetic rat heart
    • Broderick, T. L. ATP production and TCA activity are stimulated by propionyl-L-carnitine in the diabetic rat heart. Drugs in R & D 9, 83-91 (2008).
    • (2008) Drugs in R & D , vol.9 , pp. 83-91
    • Broderick, T.L.1
  • 34
    • 84986877721 scopus 로고    scopus 로고
    • Differential effects of oral and intravenous l-carnitine on serum lipids: Is the microbiota the answer?
    • Sanchez-Nino, M. D. & Ortiz, A. Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer? Clinical Kidney Journal 7, 437-441 (2014).
    • (2014) Clinical Kidney Journal , vol.7 , pp. 437-441
    • Sanchez-Nino, M.D.1    Ortiz, A.2
  • 35
    • 84877331372 scopus 로고    scopus 로고
    • Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
    • Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine 19, 576-585 (2013).
    • (2013) Nature Medicine , vol.19 , pp. 576-585
    • Koeth, R.A.1
  • 36
    • 84910129274 scopus 로고    scopus 로고
    • γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of l-carnitine to TMAO
    • Koeth, R. A. et al. γ -Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO. Cell metabolism 20, 799-812 (2014).
    • (2014) Cell Metabolism , vol.20 , pp. 799-812
    • Koeth, R.A.1
  • 37
    • 69449100622 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    • Group, P.
    • Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535, doi: 10.1136/bmj.b2535 (2009).
    • (2009) BMJ , vol.339 , pp. b2535
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 38
    • 84954421063 scopus 로고    scopus 로고
    • Higgins, J. (Chichester, UK, John Wiley and Sons Ltd. Ref Type: Report, 2010)
    • Higgins, J. (Chichester, UK, John Wiley and Sons Ltd. Ref Type: Report, 2010).
  • 40
    • 21544449115 scopus 로고    scopus 로고
    • Estimating the mean and variance from the median, range, and the size of a sample
    • Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 5, 13 (2005).
    • (2005) BMC Medical Research Methodology , vol.5 , pp. 13
    • Hozo, S.P.1    Djulbegovic, B.2    Hozo, I.3
  • 41
    • 0033934949 scopus 로고    scopus 로고
    • Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis
    • Duval, S. & Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 56, 455-463 (2000).
    • (2000) Biometrics , vol.56 , pp. 455-463
    • Duval, S.1    Tweedie, R.2
  • 42
    • 80052307183 scopus 로고    scopus 로고
    • Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]
    • Green, S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration (2011).
    • (2011) The Cochrane Collaboration
    • Green, S.1
  • 43
    • 34249709372 scopus 로고    scopus 로고
    • L-carnitine inhibits protein glycation in vitro and in vivo: Evidence for a role in diabetic management
    • Rajasekar, P. & Anuradha, C. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta diabetologica 44, 83-90 (2007).
    • (2007) Acta Diabetologica , vol.44 , pp. 83-90
    • Rajasekar, P.1    Anuradha, C.2
  • 44
    • 84925519643 scopus 로고    scopus 로고
    • Oral L-carnitine supplementation increases trimethylamine-N-oxide, but reduces markers of vascular injury in hemodialysis patients
    • Fukami, K. et al. Oral L-carnitine supplementation increases trimethylamine-N-oxide, but reduces markers of vascular injury in hemodialysis patients. Journal of cardiovascular pharmacology 65, 289-295 (2015).
    • (2015) Journal of Cardiovascular Pharmacology , vol.65 , pp. 289-295
    • Fukami, K.1
  • 45
    • 33845792003 scopus 로고    scopus 로고
    • Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis
    • Rysz, J. et al. Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 26, 437-44 (2006).
    • (2006) Am J Nephrol , vol.26 , pp. 437-444
    • Rysz, J.1
  • 46
    • 84898859680 scopus 로고    scopus 로고
    • Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-noxide
    • Wang, Z. et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-Noxide. European heart journal 35, 904-10 (2014).
    • (2014) European Heart Journal , vol.35 , pp. 904-910
    • Wang, Z.1
  • 47
    • 79953733693 scopus 로고    scopus 로고
    • Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
    • Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
    • (2011) Nature , vol.472 , pp. 57-63
    • Wang, Z.1
  • 48
    • 84925862053 scopus 로고    scopus 로고
    • Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease
    • Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116, 448-455 (2015).
    • (2015) Circ Res , vol.116 , pp. 448-455
    • Tang, W.H.1
  • 49
    • 84872139636 scopus 로고    scopus 로고
    • Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation
    • Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell metabolism 17, 49-60 (2013).
    • (2013) Cell Metabolism , vol.17 , pp. 49-60
    • Bennett, B.J.1
  • 50
    • 84907486084 scopus 로고    scopus 로고
    • The contributory role of gut microbiota in cardiovascular disease
    • Tang, W. & Hazen, S. L. The contributory role of gut microbiota in cardiovascular disease. The Journal of clinical investigation 124, 4204-4211 (2014).
    • (2014) The Journal of Clinical Investigation , vol.124 , pp. 4204-4211
    • Tang, W.1    Hazen, S.L.2
  • 51
    • 84920704729 scopus 로고    scopus 로고
    • Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis
    • Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. Journal of lipid research 56, 22-37 (2015).
    • (2015) Journal of Lipid Research , vol.56 , pp. 22-37
    • Shih, D.M.1
  • 52
    • 84921362010 scopus 로고    scopus 로고
    • The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance
    • Warrier, M. et al. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell reports. doi: 10.1016/j.celrep.2014.12.036.
    • Cell Reports
    • Warrier, M.1
  • 53
    • 84927126803 scopus 로고    scopus 로고
    • Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
    • Miao, J. et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nature communications 6, 6498 (2015).
    • (2015) Nature Communications , vol.6 , pp. 6498
    • Miao, J.1
  • 54
    • 84880197534 scopus 로고    scopus 로고
    • L-carnitine in the secondary prevention of cardiovascular disease: Systematic review and meta-analysis
    • Di Nicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R. & O'Keefe, J. H. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings 88, 544-551 (2013).
    • (2013) Mayo Clinic Proceedings , vol.88 , pp. 544-551
    • Di Nicolantonio, J.J.1    Lavie, C.J.2    Fares, H.3    Menezes, A.R.4    O'Keefe, J.H.5
  • 55
    • 84925651749 scopus 로고    scopus 로고
    • Effect of L-carnitine supplementation on circulating C-reactive protein levels: A systematic review and meta-analysis
    • ISSN (Online)
    • Sahebkar, A. Effect of L-Carnitine Supplementation on Circulating C-Reactive Protein Levels: A Systematic Review and Meta-Analysis. Journal of Medical Biochemistry 34, Pages 151-159, ISSN (Online) (2015).
    • (2015) Journal of Medical Biochemistry , vol.34 , pp. 151-159
    • Sahebkar, A.1
  • 56
    • 84904445760 scopus 로고    scopus 로고
    • Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysis
    • Shang, R., Sun, Z. & Li, H. Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC cardiovascular disorders 14, 88 (2014).
    • (2014) BMC Cardiovascular Disorders , vol.14 , pp. 88
    • Shang, R.1    Sun, Z.2    Li, H.3
  • 57
    • 84876494766 scopus 로고    scopus 로고
    • Metabolic effects of L-carnitine on type 2 diabetes mellitus: Systematic review and meta-analysis
    • Vidal-Casariego, A. et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Experimental and clinical endocrinology & diabetes 121, 234-238 (2013).
    • (2013) Experimental and Clinical Endocrinology & Diabetes , vol.121 , pp. 234-238
    • Vidal-Casariego, A.1
  • 58
    • 84893639889 scopus 로고    scopus 로고
    • Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: A systematic review and meta-analysis
    • Huang, H., Song, L., Zhang, H., Zhang, J. & Zhao, W. Influence of L-Carnitine Supplementation on Serum Lipid Profile in Hemodialysis Patients: A Systematic Review and Meta-Analysis. Kidney & blood pressure research 38, 31-41 (2014).
    • (2014) Kidney & Blood Pressure Research , vol.38 , pp. 31-41
    • Huang, H.1    Song, L.2    Zhang, H.3    Zhang, J.4    Zhao, W.5
  • 59
    • 84893352410 scopus 로고    scopus 로고
    • L-carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: A systematic review and meta-analysis
    • Chen, Y. et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. The American journal of clinical nutrition 99, 408-422 (2014).
    • (2014) The American Journal of Clinical Nutrition , vol.99 , pp. 408-422
    • Chen, Y.1
  • 60
    • 84901013879 scopus 로고    scopus 로고
    • Effect of L-carnitine therapy on patients in maintenance hemodialysis: A systematic review and meta-analysis
    • Yang, S.-k. et al. Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis. Journal of nephrology 27, 317-329 (2014).
    • (2014) Journal of Nephrology , vol.27 , pp. 317-329
    • Yang, S.-K.1
  • 61
    • 0020592202 scopus 로고
    • Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: Decisive role of low levels of high-density lipoprotein-cholesterol
    • Vacha, G. M., Giorcelli, G., Siliprandi, N. & Corsi, M. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. The American journal of clinical nutrition 38, 532-540 (1983).
    • (1983) The American Journal of Clinical Nutrition , vol.38 , pp. 532-540
    • Vacha, G.M.1    Giorcelli, G.2    Siliprandi, N.3    Corsi, M.4
  • 62
    • 0025107644 scopus 로고
    • Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects
    • Golper, T. A. et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 38, 904-911 (1990).
    • (1990) Kidney Int , vol.38 , pp. 904-911
    • Golper, T.A.1
  • 63
    • 0037945488 scopus 로고    scopus 로고
    • The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus
    • Derosa, G. et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clinical therapeutics 25, 1429-1439 (2003).
    • (2003) Clinical Therapeutics , vol.25 , pp. 1429-1439
    • Derosa, G.1
  • 64
    • 68149181537 scopus 로고    scopus 로고
    • Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus
    • Galvano, F. et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert opinion on pharmacotherapy 10, 1875-1882 (2009).
    • (2009) Expert Opinion on Pharmacotherapy , vol.10 , pp. 1875-1882
    • Galvano, F.1
  • 65
    • 77958600062 scopus 로고    scopus 로고
    • Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia
    • Shakeri, A., Tabibi, H. & Hedayati, M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodialysis international 14, 498-504, (2010).
    • (2010) Hemodialysis International , vol.14 , pp. 498-504
    • Shakeri, A.1    Tabibi, H.2    Hedayati, M.3
  • 66
    • 79958723473 scopus 로고    scopus 로고
    • Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy
    • Shojaei, M., Djalali, M., Khatami, M., Siassi, F. & Eshraghian, M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iranian journal of kidney diseases 5, 114-118 (2011).
    • (2011) Iranian Journal of Kidney Diseases , vol.5 , pp. 114-118
    • Shojaei, M.1    Djalali, M.2    Khatami, M.3    Siassi, F.4    Eshraghian, M.5
  • 67
    • 0034303187 scopus 로고    scopus 로고
    • L-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp (a)
    • Sirtori, C. et al. L-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp (a). Nutrition, metabolism, and cardiovascular diseases 10, 247-251 (2000).
    • (2000) Nutrition, Metabolism, and Cardiovascular Diseases , vol.10 , pp. 247-251
    • Sirtori, C.1
  • 68
    • 33748132593 scopus 로고    scopus 로고
    • Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus
    • Solfrizzi, V. et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis 188, 455-461 (2006).
    • (2006) Atherosclerosis , vol.188 , pp. 455-461
    • Solfrizzi, V.1
  • 69
    • 84964314006 scopus 로고    scopus 로고
    • L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: A randomized controlled study
    • Zhang, J. J. et al. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. Nutrition journal 13, 110 (2014).
    • (2014) Nutrition Journal , vol.13 , pp. 110
    • Zhang, J.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.